Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has granted tentative approval to Teva Pharmaceutical's Atorvastatin Calcium Tablets abbreviated new drug application (ANDA).
Subscribe to our email newsletter
Teva’s Atorvastatin Calcium Tablets are the generic equivalent forms of Pfizer’s Lipitor.
During Ranbaxy’s 180-day first-to-file exclusivity period, a portion of the profits from its sales of Atorvastatin Calcium Tablets will be paid to Teva asd it has launched the product.
The drug is proven that along with diet and exercise it lowers bad cholesterol and along with diet reduces the risk of heart attack and stroke in patients with heart disease or several common risk factors for heart disease.